伊马替尼联合干扰素-α治疗慢性髓细胞性白血病的疗效  

Effects of imatinib combined with interferon in treatment of chronic myelogenous leukemia

作　　者：包翠华[1] 

机构地区：[1]内蒙古包钢医院血液科,包头市014010

出　　处：《中国肿瘤临床与康复》2013年第2期174-176,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨伊马替尼联合干扰素-α治疗慢性髓细胞性白血病的疗效。方法回顾性分析50例慢性髓细胞性白血病患者的临床资料,分为接受伊马替尼联合干扰素-α治疗的观察组(28例)和接受干扰素-α治疗的对照组(22例),观察治疗后缓解情况、不良反应例数以及生活质量。结果两组患者血液学缓解情况无明显差异,观察组细胞遗传学反应情况明显好于对照组,各类不良反应例数明显少于对照组,KPS评分、躯体功能、心理功能、社会功能、认知功能和总体生活质量评分明显高于对照组。结论伊马替尼联合干扰素-α能够改善治疗的细胞遗传学反应、减少不良反应例数、提高患者生活质量,是行之有效的治疗方式。Objective To study the effects of imatinib combined with interferon in treatment of chronic myelogenous leukemia （CML）. Methods 50 cases of CML patients were retrospectively studied and divided into observation group（ treated by imatinib combined with interferon） and control group（ treated by interferon）. Then remission, adverse reaction and quality of life were observed. Results Haematological remission of two groups were not obviously different, cytogenetic response of observation group was obviously better than control group, all kinds of adverse reactions were significantly less than control group, KPS score and overall quality of life score were significantly higher than those of control group. Conclusions imatinib combined with interferon can improve the treatment of cytogenetic response, reduce the adverse re- action cases, improve the quality of life.

关 键 词：慢性髓细胞性白血病 伊马替尼 干扰素 细胞遗传学反应 

分 类 号：R733.72[医药卫生—肿瘤]